The role of external beam radiation therapy (EBRT) in the management of thyroid cancer is not clearly defined. In the absence of randomized studies, the review aims to identify any recent literature that helps define the role.
INTRODUCTION
The use of external beam radiotherapy (EBRT) in thyroid cancer is limited to high-risk patients and the evidence of its benefit comes from single institution retrospective series. The recent advances have come especially in the management of anaplastic thyroid cancer (ATC). Improvements in the delivery of EBRT with the use of intensity-modulated radiotherapy (IMRT) should reduce toxicity. The recent evidence and role for EBRT will be considered for differentiated thyroid carcinoma (DTC), medullary carcinoma and anaplastic thyroid carcinoma.
DIFFERENTIATED THYROID CARCINOMA
DTC refers to several histological variants most commonly papillary thyroid carcinoma and less commonly follicular thyroid carcinoma, and Hurthle cell carcinoma. The latter have less favorable prognosis compared with papillary thyroid carcinoma [1] .
By far, the commonest form of radiation therapy used in the management of DTC is 131 Iodine combined with thyroid stimulating hormone (TSH) suppression. 131 Iodine has been shown to reduce locoregional recurrence and improve survival in well selected patients [2] . However, there is increasing evidence that more patients require no further therapy following surgery and further studies are ongoing to better define these patient cohorts to avoid unnecessary therapy [2] [3] [4] . This article will review the more selective and controversial role of EBRT in DTC.
There is a lack of prospective evidence to guide the management of locally advanced DTC. One randomized clinical trial was attempted; however, it was closed because of poor accrual [5] . This study randomized patients with pT3/4 pN0/1/X without distant metastasis following an R0 (no residual disease) or R1 (microscopic residual) resection 131 Iodine and TSH suppression therapy to observation or EBRT. The dose or EBRT was 59.4Gy if R0 resection and 66.6Gy if R1 resection [5] . This trial was converted into a prospective cohort study. Although EBRT was generally well tolerated the recurrence rate was 0% for those treated with EBRT and 3% for those with observation. The patients on the observation arm who developed recurrence subsequently underwent salvage surgical procedures. There was no difference in long-term outcome between the two arms. The study has been criticized because most patients entered would not have met either the American Thyroid Association (ATA) or the British Thyroid Association (BTA) guidelines on the use of EBRT, and therefore would not have been expected to have benefited [6] .
Single institution experiences have attempted to define the population of DTC that would benefit from EBRT. In a series from Memorial Sloan Kettering (MSK) of patients with T2-T4, N0/1 patients who received EBRT (median dose 62 Gy interquartile range 59.4-67.5 Gy) the 4-year locoregional control was 72%. However, EBRT can cause significant acute toxicity including mucositis and esophagitis. EBRT can also have lasting effects including feeding tube dependence, xerostomia and osteoradionecrosis. In the MSK experience, 5% of patients were dependent on feeding tubes following EBRT [7] . In a report on quality of life (QOL), not surprisingly patients who had EXRT had more pain and dysphagia than patients who had 131 Iodine only [8] . Other single institutional studies from the UK and the USA also report high local regional control rates in high-risk patients after EBRT. The MD Anderson group reported a local relapse free rate of 79% at 4 years [9] . The Christie Hospital, UK reported a 5-year locoregional control rate of 89.1% for those with clear or microscopic positive margins and 69.2% for patients with macroscopic residual or inoperable disease [10] . Both concluded that in patients with high-risk DTC EBRT provided durable locoregional disease control. The MD Anderson group also reported that IMRT was associated with less frequent late toxicity. Our institutional data have shown that the use of EBRT in patients aged more than 60 with extrathyroidal extension significantly improved local relapse free rate from 87.5 to 96% at 5 years with a small survival benefit [11] .
The ATA and NCCN guidelines recommends consideration of EBRT in patients aged more than 45 years with gross extrathyroidal extension and high likelihood of microscopic residual disease [12, 13] . EBRT should also be considered in patients with gross residual disease. The British Thyroid Association have similar recommendations but for patients more than 60 years old [14] . It is our current institutional policy to recommend EBRT in patients usually over 50 with gross extrathyroid extension that invades posteriorly into the tracheaesophageal groove that is unlikely to be controlled by 131 Iodine and in whom salvage surgery may require an ablative procedure sacrificing the larynx or esophagus (T4a or T4b). Patients with minimal extrathyroid extension (ETE) (T3) even with positive margins or ETE that invades anteriorly into the strap muscles can usually be resected with clear margins and do not require EBRT. We also recommend EBRT in patients who have repeated surgery for recurrent nodal involvement and in whom further surgery would be problematic.
In our institution, surgeons routinely perform computed tomography (CT) scans with contrast in patients with pain, recurrent laryngeal palsy, size greater than 4 cm or other poor prognostic features that may predict for ETE. This helps the surgeon plan the surgery but also is a huge benefit to the radiation oncologist in planning any radiation therapy and is preferable to MRI in identifying involved lymph nodes and cartilage involvement. In the past, many experts have recommended against CT scan with contrast because of concerns that the iodine in the contrast would reduce the efficacy of any subsequent 131 Iodine therapy. A recent study, however, reported that with modern water-soluble contrast media only a 1-month delay is required for the urinary iodine levels to fall to base line [15 & ]. A second study, however, recommended 2 months [16] . Our current practice is not to administer 131 Iodine for 2 months after CT scan with contrast; this does not result in any meaningful delay.
EBRT has been recommended in patients with poorly differentiated or insular thyroid cancer and less extensive ETE (T3); however, there are no data to support this, although it does not seem
KEY POINTS
EBRT can increase locoregional control and possibly survival in older patients with extrathyroidal extension with differentiated thyroid cancer.
EBRT can improve survival in addition to surgery in selected patients with ATC.
IMRT significantly improves side-effects such as xerostomia following radiotherapy.
The optimal radiation volumes in thyroid cancer remain controversial.
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unreasonable [17] . The role of EBRT in patients with DTC and a small component of undifferentiated carcinoma or ATC remains controversial. In some circumstances, in the absence of extrathyroidal extension, these patients may be observed following thyroidectomy, radioactive iodine and TSH suppression [18 && ]. In the palliative setting, either unresectable disease in the thyroid or neck or distant metastasis (bone, lung, brain) EBRT can play a role in palliation of symptoms including pain, bleeding and confer a period of local control [12] .
Balancing the risk of recurrence with the risk of acute and late effects from EBRT is critical in determining therapy for patients with locally advanced (pT3/4, N0/1) DTC. In patients who require EBRT, minimizing radiotherapy volumes can reduce sideeffects but must not compromise locoregional disease control. The optimal target volume for EBRT is controversial. Larger elective target volumes have the potential to reduce recurrence; however, they can be associated with increased toxicity. The late effects following EBRT to the head and neck region are dependent on the volumes radiated and the dose to normal structures. Structures of particular concern include the parotid glands [19] as dose to the parotid glands impacts xerostomia, the pharyngeal constrictors [20] that impacts swallowing and feeding tube dependence and the mandible [21] , which can influence the occurrence of osteoradionecrosis. By delivering the lowest effective radiotherapy dose to the smallest well tolerated volume, the risk of late effects is minimized.
It is our institutional practice to include the surgical thyroidectomy bed and levels III, IV, VI and part of level V. The volumes extend from the hyoid bone superiorly to the aortic arch inferiorly. However, two recent publications question the need for larger target volumes. One article compared patients who received limited field EBRT (including the tumor bed and positive nodal regions) compared with the extended radiotherapy volumes (including the tumor bed, involved nodal regions and elective coverage of cervical and upper mediastinal nodal regions). They divided recurrences into in field and out of field. They reported no out-of-field failures in the extended field group and significantly improved locoregional control (40 vs. 89%) [22] . In the second article, upper mediastinal failures are reported and a recommendation is made to extend treatment volumes to the level of the carina [10] . However, this issue should be revisited in patients treated with CT-based simulation and IMRT planning, as extension of the radiotherapy volumes to encompass the mediastinum can place the patient at risk of radiation pneumonitis.
Regardless of the radiotherapy volume delineated, EBRT should be delivered using IMRT techniques. IMRT allows modulation of the intensity of the radiotherapy beam to facilitate treatment of the target volume and sparing of organs at risk (Fig. 1) . IMRT has been shown in randomized studies in other head and neck cancers to reduce sideeffects, namely xerostomia, and improve QOL compared with 2D or 3D techniques [23, 24] .
MEDULLARY THYROID CARCINOMA
Medullary thyroid carcinoma (MTC) is a rare form of thyroid carcinoma. The hereditary nature of MTC has been reviewed in a separate article in this volume. Therapy is guided by institutional experiences and because of the rarity of the disease it is challenging to have conclusive results. The principle management for MTC is surgical resection. MTC does not take up 131 Iodine. In an analysis of surveillance, epidemiology, and end results (SEER) data, the addition of EBRT to patients with involved lymph nodes did not show a survival advantage [25] . However, improving locoregional control is beneficial and the role of EBRT in selected patients is supported by institutional experiences. Patients in one study who received surgery followed by adjuvant radiotherapy (60 Gy) had an 87% 5-year locoregional relapse-free survival with the majority of relapse being distant [26] . In another study, patients with locally advanced disease had a locoregional failure rate of only 33% [7] . Unfortunately, patients who present with locally advanced MTC invariably have metastatic disease, and therefore, although EBRT can improve local control, survival is not improved. Currently, we recommend EBRT only in patients with locally advanced disease that is unresectable or in patients with gross ETE in who after resection subsequent relapse would result in uncontrollable disease.
ANAPLASTIC THYROID CARCINOMA
Anaplastic thyroid carcinoma does not take up 131 Iodine; therefore, EBRT and surgical resection are the mainstays of treatment. EBRT may be employed in the adjuvant setting after surgical resection or as primary treatment in patients who are not able to have surgery. In an analysis of SEER data, EBRT in addition to surgical resection improves survival for patients with T4b disease [27] . In a recent study (summarized in Table 1 ), of 2742 patients identified with ATC from 1998 to 2008 in the National Cancer Database in patients with locally advanced disease (stage IVb), the addition of radiation or radiation and chemotherapy to surgery resulted in a significant improvement in median survival from 2 months (surgery alone) to 6 months (surgery and radiation) and 10 months (surgery, radiation and chemotherapy). The difference between the surgery and radiation and the surgery, radiation and chemotherapy groups was not statistically significant [28 & ]. ATC is characterized by rapid growth and disease progression and this has resulted in the use of accelerated and hyperfractionated radiotherapy schedules. These altered fractionation regimens are thought to compensate for tumor repopulation [6] . A retrospective series by Wang et al.
[29] reported a trend for increased median survival with twice daily radiotherapy; however, this was not statistically significant. Twice daily accelerated regimens are intense for patients, and careful patient selection is essential. It is the practice at Princess Margaret Cancer Centre to give these patients 60 Gy in 40 fractions delivered in 1.5 Gy per fraction with two fractions per day over 4 weeks [29] to medically fit patients in an attempt to maximize locoregional control. Patients not suitable for radical treatment receive palliative radiotherapy, most commonly 2000cGy in five fractions, which can be repeated.
Radiotherapy alone, even altered fractionated regimens, still result in high rates of local failure and poor overall patient outcomes. Chemotherapy, often doxorubicin, has been given in combination with radiotherapy in an attempt to improve outcomes [30] [31] [32] . Doxorubicin is given weekly, 10 mg/ m 2 , in combination with radiotherapy, preferably hyperfractionated regimens [32] . Doxorubicin in combination with EBRT in ATC has been shown to have a median locoregional progression free survival of 10.1 months (increased to 35.9 months if greater than 50 Gy of radiotherapy was used) [32] . Although at least five cycles of doxorubicin was significant on univariate analysis, it was not significant on multivariate analysis [6] . Combining chemotherapy with altered fractionation radiotherapy schedules is associated with significant toxicity [30, 33] . The true superiority of such combinations is not known.
More recent reports of concurrent chemoradiation have used more conventional radiation sensitizing agents such as the platins or taxanes. In a report of six patients treated with EBRT and docetaxel 100 mg every 3 weeks for six cycles, the median survival was 15.6 months. The treatment was not without toxicity with mucostitis/stomatitis, esophagitis and dermatitis, and all patients required hospitalization for nutritional support [34] . In a series of 10 patients with IVA or IVB disease treated by surgery if possible, followed by IMRT and four cycles of chemotherapy (docetaxel and doxorubicin being the commonest), the median survival was 44 months, and the 2-year survival was 60% [35] . Two of the 10 required hospitalization because of toxicity. In patients with regionally confined ATC, an aggressive multimodality approach may be warranted, but the toxicity appears significant, which is problematic in a group of patients with such a poor life expectancy. In the recently published comprehensive guidelines on the management of ATC from the ATA, although multimodality therapy was recommended for ].
The optimal radiotherapy volumes to be included in radical and adjuvant radiotherapy for anaplastic thyroid carcinoma is an area of debate. It is our institutional practice to include the gross disease with a 1 cm margin or the postsurgical bed with a 1 cm margin for clinical target volume (CTV). Elective nodal regions, which are included in the radiotherapy volumes, include levels 3,4,6 and part of level 5 [35] . The radiotherapy fields generally extend from the hyoid to the suprasternal notch [29] . However, more comprehensive radiotherapy volumes have been used that include levels II-VI and the upper mediastinal nodes to the level of the carina. In some circumstances, level I and the retropharyngeal nodes are also included [36] .
CONCLUSION
EBRT is able to improve locoregional control in patients with thyroid cancer, and in some cases, may improve survival. Careful consideration of radiotherapy volumes to minimize toxicity is needed. IMRT is highly advantageous to reduce radiation dose to organs at risk and potentially improve late outcomes. Further work is needed to accurately identify the patients who benefit most from therapy and to refine the minimum volume that requires radiotherapy.
